MX2010011193A - Liquid pharmaceutical composition for pain treatment and prevention. - Google Patents

Liquid pharmaceutical composition for pain treatment and prevention.

Info

Publication number
MX2010011193A
MX2010011193A MX2010011193A MX2010011193A MX2010011193A MX 2010011193 A MX2010011193 A MX 2010011193A MX 2010011193 A MX2010011193 A MX 2010011193A MX 2010011193 A MX2010011193 A MX 2010011193A MX 2010011193 A MX2010011193 A MX 2010011193A
Authority
MX
Mexico
Prior art keywords
prevention
pharmaceutical composition
liquid pharmaceutical
pain treatment
treatment
Prior art date
Application number
MX2010011193A
Other languages
Spanish (es)
Inventor
Armenta Maria Elena Garcia
Murillo Josefina Santos
Ochoa Victor Guillermo Alvarez
Original Assignee
World Trade Imp Exp Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Exp Wtie Ag filed Critical World Trade Imp Exp Wtie Ag
Priority to MX2010011193A priority Critical patent/MX2010011193A/en
Priority to PCT/IB2011/002373 priority patent/WO2012049550A1/en
Priority to ARP110103770A priority patent/AR083393A1/en
Publication of MX2010011193A publication Critical patent/MX2010011193A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a liquid pharmaceutical composition in solution, formulated to be administered orally as drops, comprising the synergic combination of ketorolac and tramadol, as well as pharmaceutically acceptable excipients, which can be used in the prevention and treatment of moderate to severe pain in paediatric patients without causing adverse side effects.
MX2010011193A 2010-10-12 2010-10-12 Liquid pharmaceutical composition for pain treatment and prevention. MX2010011193A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2010011193A MX2010011193A (en) 2010-10-12 2010-10-12 Liquid pharmaceutical composition for pain treatment and prevention.
PCT/IB2011/002373 WO2012049550A1 (en) 2010-10-12 2011-10-10 Liquid pharmaceutical composition for pain treatment and prevention
ARP110103770A AR083393A1 (en) 2010-10-12 2011-10-12 PHARMACEUTICAL COMPOSITION LIQUID FOR THE TREATMENT AND PREVENTION OF PAIN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010011193A MX2010011193A (en) 2010-10-12 2010-10-12 Liquid pharmaceutical composition for pain treatment and prevention.

Publications (1)

Publication Number Publication Date
MX2010011193A true MX2010011193A (en) 2012-04-18

Family

ID=45937950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011193A MX2010011193A (en) 2010-10-12 2010-10-12 Liquid pharmaceutical composition for pain treatment and prevention.

Country Status (3)

Country Link
AR (1) AR083393A1 (en)
MX (1) MX2010011193A (en)
WO (1) WO2012049550A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019143234A1 (en) 2018-01-22 2019-07-25 AMÉZCUA AMÉZCUA, Federico Synergistic pharmaceutical combination of the active enantiomer s-ketorolac tromethamine and tramadol chlorhydrate

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014005152A (en) * 2014-04-29 2015-10-28 Liomont S A De C V Lab Pharmaceutical composition for the treatment of allopathic pain, using ketorolac tromethamine and tramadol hydrochloride as an active ingredient.
WO2019122982A1 (en) 2017-12-21 2019-06-27 Grünenthal GmbH Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment
GR1009629B (en) * 2018-02-20 2019-10-25 Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. Orally-administrated tramadol-containing solutions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010828A (en) * 2002-11-04 2004-07-16 Leopoldo Espinosa Abdala Pharmaceutical composition in capsules comprising a non-steroidal anti-inflammatory and an opiate analgesic for handling pain.
MXPA03012048A (en) * 2003-12-19 2005-06-23 Victor Guillermo Alvarez Ochoa Pharmaceutical composition in capsules comprising a non-steroidal anti-inflammatory and an opiate analgesic for handling pain.
MX2007003948A (en) * 2007-04-02 2009-02-25 World Trade Imp Export Wtie Ag Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019143234A1 (en) 2018-01-22 2019-07-25 AMÉZCUA AMÉZCUA, Federico Synergistic pharmaceutical combination of the active enantiomer s-ketorolac tromethamine and tramadol chlorhydrate

Also Published As

Publication number Publication date
AR083393A1 (en) 2013-02-21
WO2012049550A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
EA201491285A1 (en) IMPROVED COMPOSITIONS AND METHODS OF DELIVERY OF OMEPRAZOL AND ACETYLSALICYLIC ACID
NZ714963A (en) Compositions and methods for treating anemia
ES2916649T1 (en) Compositions and uses for the treatment of multiple sclerosis
WO2012007159A3 (en) Novel gastro-retentive dosage forms
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX2014002171A (en) Combination treatments for hepatitis c.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
MX2012000488A (en) Combination therapy for the treatment of diabetes.
MX2018008021A (en) Methods and compositions for the treatment of seizure-related disorders.
MX2013000694A (en) Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease.
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
MX2015001917A (en) Pharmaceutical compositions of memantine.
WO2012053013A3 (en) Pharmaceutical compositions of anti-acne agents
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2010011193A (en) Liquid pharmaceutical composition for pain treatment and prevention.
MX2013003523A (en) Low dose pharmaceutical composition comprising zanamivir.
MX2016008027A (en) Use of laquinimod to delay huntington's disease progression.

Legal Events

Date Code Title Description
GD Licence granted
GD Licence granted
GB Transfer or assignment

Owner name: PPTM INTERNATIONAL, S.A.R.L.

GD Licence granted
GD Licence granted
FA Abandonment or withdrawal